journal article·2018-10-31Open access

TAK1 mediates apoptosis via p38 involve in ischemia-induced renal fibrosis

Jun Zhou, Jiying Zhong, Zhenxing Huang, Meijuan Liao, Sen Lin, Jia Chen, Hongtao Chen

Abstract

Renal fibrosis is a common and characteristic symptom of chronic kidney disease (CKD). However, the molecular mechanisms of renal fibrosis remain elusive. Ischemia injury, as a major cause of AKI, deserves more attention in order to improve the knowledge of AKI-induced fibrosis. Transforming growth factor-β (TGF-β)-activated kinase 1 (TAK1) interacts directly with TGF-β, which play a critical role in the progression of fibrosis. Therefore, the present study aimed to investigate the role of TAK1 in the pathogenesis of ischemia-induced renal fibrosis. Compared with mice in the vehicle group, mice intraperitoneally injected with TAK1 inhibitor were found to have lower serum creatinine, less tubular damage and more mild fibrosis following ischemia-induced AKI. Furthermore, inhibition of TAK1 reduced p38 phosphorylation, decreased expression of Bax and caspase 3 and apoptosis cells in kidneys of mice treated with IR-induced AKI. Compared with vehicle-treated renal tubular epithelial cells, TAK1 overexpression cells were found to have a higher apoptosis and fibrosis index level and p38 phosphorylation following hypoxia/reoxygenation (H/R) treatment. Furthermore, the p38 inhibitor combined with TAK1 overexpression verified the role of TAK1/p38 signaling pathway in apoptosis and fibrosis index level of renal tubular epithelial cells treated with H/R. Thus, our results show that TAK1 plays an important role in the pathogenesis of ischemia-induced renal fibrosis and may mediate p38-regulated cell apoptosis.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Acute Kidney Injury Research · Chronic Kidney Disease and Diabetes · Heavy Metal Exposure and Toxicity

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Anesthesiology, The First People’s Hospital of Foshan

Department of Anesthesiology, The Eighth People’s Hospital of Guangzhou

Funding

National Natural Science Foundation of Guangdong Province

References (38)

Show source-provided references
1. 10.1016/S0140-6736(16)32064-510.1016/S0140-6736(16)32064-5 ↗
2. 10.1097/MNH.0b013e3283521cfa10.1097/MNH.0b013e3283521cfa ↗
3. 10.1681/ASN.201008079310.1681/ASN.2010080793 ↗
4. 10.1046/j.1523-1755.2002.00430.x10.1046/j.1523-1755.2002.00430.x ↗
5. 10.1016/j.bbrc.2015.11.09210.1016/j.bbrc.2015.11.092 ↗
6. 10.1681/ASN.200405042510.1681/ASN.2004050425 ↗
7. 10.1371/journal.pone.016085510.1371/journal.pone.0160855 ↗
8. 10.1038/nrneph.2015.310.1038/nrneph.2015.3 ↗
9. 10.1097/TP.000000000000167910.1097/TP.0000000000001679 ↗
10. 10.1186/s12882-016-0348-x10.1186/s12882-016-0348-x ↗
11. 10.1016/j.semnephrol.2013.11.00910.1016/j.semnephrol.2013.11.009 ↗
12. 10.1152/ajprenal.00365.201510.1152/ajprenal.00365.2015 ↗
13. 10.1038/cdd.2014.12310.1038/cdd.2014.123 ↗
14. 10.3892/or.2017.540210.3892/or.2017.5402 ↗
15. 10.1080/0886022X.2017.130540910.1080/0886022X.2017.1305409 ↗
16. Wang Y, Zhang J, Zhang L, et al. Adiponectin attenuates high glucose-induced apoptosis through the AMPK/p38 MAPK signaling pathway in NRK-52E cells. PLoS One. 2017;12:e0178215.10.1371/journal.pone.0178215 ↗
17. Yuen CM, Yeh KH, Wallace CG, et al. EPO-cyclosporine combination therapy reduced brain infarct area in rat after acute ischemic stroke: role of innate immune-inflammatory response, micro-RNAs and MAPK family signaling pathway. Am J Transl Res. 2017;9:1651–1666.
18. 10.18632/oncotarget.938610.18632/oncotarget.9386 ↗
19. 10.1159/00048407010.1159/000484070 ↗
20. 10.1080/0886022X.2016.119416510.1080/0886022X.2016.1194165 ↗
21. 10.1159/00032932510.1159/000329325 ↗
22. 10.1155/2014/80284110.1155/2014/802841 ↗
23. 10.1016/j.ajpath.2015.08.00310.1016/j.ajpath.2015.08.003 ↗
24. 10.1016/j.semnephrol.2012.04.00310.1016/j.semnephrol.2012.04.003 ↗
25. 10.1016/j.krcp.2012.04.32210.1016/j.krcp.2012.04.322 ↗
26. 10.1093/jmcb/mju03010.1093/jmcb/mju030 ↗
27. 10.1016/j.ejphar.2017.06.00910.1016/j.ejphar.2017.06.009 ↗
28. 10.5500/wjt.v5.i2.5210.5500/wjt.v5.i2.52 ↗
29. 10.1016/j.cellsig.2014.03.01510.1016/j.cellsig.2014.03.015 ↗
30. 10.1038/cddis.2017.44310.1038/cddis.2017.443 ↗
31. 10.1152/ajprenal.00010.200710.1152/ajprenal.00010.2007 ↗
32. 10.1155/2016/101539010.1155/2016/1015390 ↗
33. 10.1152/ajprenal.00485.200610.1152/ajprenal.00485.2006 ↗
34. 10.1152/ajprenal.00018.201110.1152/ajprenal.00018.2011 ↗
35. 10.3892/etm.2017.447310.3892/etm.2017.4473 ↗
36. 10.1152/ajprenal.00158.200710.1152/ajprenal.00158.2007 ↗
37. 10.1681/ASN.201008088110.1681/ASN.2010080881 ↗
38. 10.1371/journal.pone.005241510.1371/journal.pone.0052415 ↗